PLATELETE RICH PLASMA (PRP)
All female babies have around 2 million eggs in their ovaries when they are born, and this seemingly huge warehouse dwindles to around 400.000 by the time of puberty. An average of 1000 eggs are lost each month. From the mid-30s onwards, both the number of eggs and the quality of the eggs have deteriorated significantly. Towards the middle of the 40s, the ovarian stores are almost non-existent. This process is a process that develops normally in the ovaries of women, followed by the menopausal period.
In a normal menstrual cycle, we observe a certain number of eggs each month with ultrasound, and one of them matures, cracks and passes into the tube, this process is called ovulation. While one of every 30-2 eggs in a 3-year-old woman is chromosomally correct, this ratio decreases to one in 40-5 eggs at the age of 6.
In order for pregnancy to occur in normal ways and to achieve pregnancy in in vitro fertilization applications, egg drafts should be displayed in the ovaries ultrasonographically. Each egg that will develop at this stage will have a significant contribution to pregnancy outcomes. At this stage, it has come to the fore that PRP treatment can be beneficial on ovarian deposits in the last year in the world.
“PRP” (Platelet Rich Plasma), also known as Platelet Rich Plasma, is a method prepared from the person's own blood and used to stimulate and regulate healing in many areas of medicine. With the help of dozens of PRP preparation kits in use, 10-60 ml of blood is taken from the patient, this blood is separated with special disposable filters and centrifuge devices and unwanted parts are removed. The separated 2-6 ml portion contains PRP. The idea that the presence of some growth factors in this serum may be beneficial when applied to a group of patients with reduced ovarian reserves has been brought to the fore. Injecting it into the ovary for this purpose can activate some cells that are silent in the ovaries and cause them to have an effect within a few months after the procedure. Since there are a very limited number of scientific studies in the world, it is useful to be cautious about giving very clear information about this method and making big promises to patients. However, it should be taken into consideration that ovarian activity can only be obtained with a limited number of data as a result of short-term applications in the world.
In a normal menstrual cycle, we observe a certain number of eggs each month with ultrasound, and one of them matures, cracks and passes into the tube, this process is called ovulation. While one of every 30-2 eggs in a 3-year-old woman is chromosomally correct, this ratio decreases to one in 40-5 eggs at the age of 6.
In order for pregnancy to occur in normal ways and to achieve pregnancy in in vitro fertilization applications, egg drafts should be displayed in the ovaries ultrasonographically. Each egg that will develop at this stage will have a significant contribution to pregnancy outcomes. At this stage, it has come to the fore that PRP treatment can be beneficial on ovarian deposits in the last year in the world.
“PRP” (Platelet Rich Plasma), also known as Platelet Rich Plasma, is a method prepared from the person's own blood and used to stimulate and regulate healing in many areas of medicine. With the help of dozens of PRP preparation kits in use, 10-60 ml of blood is taken from the patient, this blood is separated with special disposable filters and centrifuge devices and unwanted parts are removed. The separated 2-6 ml portion contains PRP. The idea that the presence of some growth factors in this serum may be beneficial when applied to a group of patients with reduced ovarian reserves has been brought to the fore. Injecting it into the ovary for this purpose can activate some cells that are silent in the ovaries and cause them to have an effect within a few months after the procedure. Since there are a very limited number of scientific studies in the world, it is useful to be cautious about giving very clear information about this method and making big promises to patients. However, it should be taken into consideration that ovarian activity can only be obtained with a limited number of data as a result of short-term applications in the world.
